miR-577 suppresses cell proliferation and epithelial-mesenchymal transition by regulating the WNT2B mediated Wnt/β-catenin pathway in non-small cell lung cancer

Wang,Bin; Sun,Liwei; Li,Jinduo; Jiang,Rong

doi:10.3892/mmr.2018.9279

miR-577 suppresses cell proliferation and epithelial-mesenchymal transition by regulating the WNT2B mediated Wnt/β-catenin pathway in non-small cell lung cancer

Authors:
- Bin Wang
- Liwei Sun
- Jinduo Li
- Rong Jiang
View Affiliations

Affiliations: Department of Interventional Radiology, Tianjin Huanhu Hospital, Tianjin 300350, P.R. China
Published online on: July 16, 2018 https://doi.org/10.3892/mmr.2018.9279
Pages: 2753-2761
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs/miRs) serve important roles in regulating malignant phenotype in numerous cancers, such as non-small cell lung cancer (NSCLC); however, the role and function of miR-577 in NSCLC remains unknown. In the present study, miR-577 expression levels were observed to be downregulated in NSCLC via reverse transcription-quantitative polymerase chain reaction (RT-qPCR) assay, and inhibited cell proliferation, cell migration and invasion and epithelial-mesenchymal transition progress in NSCLC cells. The predicted target genes of miR-577 were determined by enhanced green fluorescent protein reporter assay, RT-qPCR and western blot analyses. miR-577 was demonstrated to suppress the expression of WNT2B by targeting the 3'-untranslated region of WNT2B mRNA in H522 and A549 cells. WNT2B was upregulated in NSCLC cells as observed via RT-qPCR analysis, and the malignant phenotype of H522 and A549 cells were promoted by WNT2B overexpression. In addition, miR-577 inactivated the Wnt/β-catenin pathway by targeting WNT2B in NSCLC cells. Collectively, miR-577 may function as a suppressor gene by directly downregulatingWNT2B mRNA and protein expression levels in H522 and A549 cells, and may serve important roles in the malignancy of NSCLC.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Osugi J, Muto S, Matsumura Y, Higuchi M, Suzuki H and Gotoh M: Prognostic impact of the high-sensitivity modified Glasgow prognostic score in patients with resectable non-small cell lung cancer. J Cancer Res Ther. 12:945–951. 2016. View Article : Google Scholar : PubMed/NCBI
3	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
4	Buettner R, Wolf J and Thomas RK: Lessons learned from lung cancer genomics: The emerging concept of individualized diagnostics and treatment. J Clin Oncol. 31:1858–1865. 2013. View Article : Google Scholar : PubMed/NCBI
5	Ramnath N, Dilling TJ, Harris LJ, Kim AW, Michaud GC, Balekian AA, Diekemper R, Detterbeck FC and Arenberg DA: Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 143 5 Suppl:e314S–e340S. 2013. View Article : Google Scholar : PubMed/NCBI
6	Novaes FT, Cataneo DC, Junior Ruiz RL, Defaveri J, Michelin OC and Cataneo AJ: Lung cancer: Histology, staging, treatment and survival. J Bras Pneumol. 34:595–600. 2008. View Article : Google Scholar : PubMed/NCBI
7	Zaporozhchenko IA, Morozkin ES, Skvortsova TE, Ponomaryova AA, Rykova EY, Cherdyntseva NV, Polovnikov ES, Pashkovskaya OA, Pokushalov EA, Vlassov VV and Laktionov PP: Plasma miR-19b and miR-183 as potential biomarkers of lung cancer. PLoS One. 11:e01652612016. View Article : Google Scholar : PubMed/NCBI
8	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
9	Ameres SL and Zamore PD: Diversifying microRNA sequence and function. Nat Rev Mol Cell Biol. 14:475–488. 2013. View Article : Google Scholar : PubMed/NCBI
10	Chen CZ: MicroRNAs as oncogenes and tumor suppressors. N Engl J Med. 353:1768–1771. 2005. View Article : Google Scholar : PubMed/NCBI
11	Yu N, Zhang Q, Liu Q, Yang J and Zhang S: A meta-analysis: MicroRNAs' prognostic function in patients with nonsmall cell lung cancer. Cancer Med. 6:2098–2105. 2017. View Article : Google Scholar : PubMed/NCBI
12	Chen Y, Lu L, Feng B, Han S, Cui S, Chu X, Chen L and Wang R: Non-coding RNAs as emerging regulators of epithelial to mesenchymal transition in non-small cell lung cancer. Oncotarget. 8:36787–36799. 2017.PubMed/NCBI
13	Legras A, Pécuchet N, Imbeaud S, Pallier K, Didelot A, Roussel H, Gibault L, Fabre E, Le Pimpec-Barthes F, Laurent-Puig P and Blons H: Epithelial-to-mesenchymal transition and MicroRNAs in lung cancer. Cancers (Basel). 9:pii: E101. 2017. View Article : Google Scholar : PubMed/NCBI
14	Sun Y, Li L, Xing S, Pan Y, Shi Y, Zhang L and Shen Q: miR-503-3p induces apoptosis of lung cancer cells by regulating p21 and CDK4 expression. Cancer Biomark. 20:597–608. 2017. View Article : Google Scholar : PubMed/NCBI
15	Li Y, Zhang H, Dong Y, Fan Y, Li Y, Zhao C, Wang C, Liu J, Li X, Dong M, et al: MiR-146b-5p functions as a suppressor miRNA and prognosis predictor in non-small cell lung cancer. J Cancer. 8:1704–1716. 2017. View Article : Google Scholar : PubMed/NCBI
16	Huang LX, Hu CY, Jing L, Wang MC, Xu M, Wang J, Wang Y, Nan KJ and Wang SH: microRNA-219-5p inhibits epithelial-mesenchymal transition and metastasis of colorectal cancer by targeting lymphoid enhancer-binding factor 1. Cancer Sci. 108:1985–1995. 2017. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Wong N and Wang X: miRDB: An online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 43:(Database Issue). D146–D152. 2015. View Article : Google Scholar : PubMed/NCBI
19	Hou J, Meng F, Chan LW, Cho WC and Wong SC: Circulating plasma MicroRNAs as diagnostic markers for NSCLC. Front Genet. 7:193eCollection. 2016. View Article : Google Scholar : PubMed/NCBI
20	Del Vescovo V and Denti MA: microRNA and lung cancer. Adv Exp Med Biol. 889:153–177. 2015. View Article : Google Scholar : PubMed/NCBI
21	Jiang H, Ju H, Zhang L, Lu H and Jie K: microRNA-577 suppresses tumor growth and enhances chemosensitivity in colorectal cancer. J Biochem Mol Toxicol. 31:2017. View Article : Google Scholar
22	Chen XY, Li GM, Dong Q and Peng H: MiR-577 inhibits pancreatic β-cell function and survival by targeting fibroblast growth factor 21 (FGF-21) in pediatric diabetes. Genet Mol Res. 14:15462–15470. 2015. View Article : Google Scholar : PubMed/NCBI
23	Wang LY, Li B, Jiang HH, Zhuang LW and Liu Y: Inhibition effect of miR-577 on hepatocellular carcinoma cell growth via targeting β-catenin. Asian Pac J Trop Med. 8:923–929. 2015. View Article : Google Scholar : PubMed/NCBI
24	Yuan X, He J, Sun F and Gu J: Effects and interactions of MiR-577 and TSGA10 in regulating esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 6:2651–2667. 2013.PubMed/NCBI
25	Farazi TA, Juranek SA and Tuschl T: The growing catalog of small RNAs and their association with distinct Argonaute/Piwi family members. Development. 135:1201–1214. 2008. View Article : Google Scholar : PubMed/NCBI
26	Majidinia M, Aghazadeh J, Jahanban-Esfahlani R and Yousefi B: The roles of Wnt/β-catenin pathway in tissue development and regenerative medicine. J Cell Physiol. 233:5598–5612. 2018. View Article : Google Scholar : PubMed/NCBI
27	Murillo-Garzón V and Kypta R: WNT signalling in prostate cancer. Nat Rev Urol. 14:683–696. 2017. View Article : Google Scholar : PubMed/NCBI
28	Nusse R and Clevers H: Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell. 169:985–999. 2017. View Article : Google Scholar : PubMed/NCBI
29	Katoh M: Differential regulation of WNT2 and WNT2B expression in human cancer. Int J Mol Med. 8:657–660. 2001.PubMed/NCBI
30	Liu C, Li G, Yang N, Su Z, Zhang S, Deng T, Ren S, Lu S, Tian Y, Liu Y and Qiu Y: miR-324-3p suppresses migration and invasion by targeting WNT2B in nasopharyngeal carcinoma. Cancer Cell Int. 17:22017. View Article : Google Scholar : PubMed/NCBI
31	Wang H, Fan L, Xia X, Rao Y, Ma Q, Yang J, Lu Y, Wang C, Ma D and Huang X: Silencing Wnt2B by siRNA interference inhibits metastasis and enhances chemotherapy sensitivity in ovarian cancer. Int J Gynecol Cancer. 22:755–761. 2012. View Article : Google Scholar : PubMed/NCBI